KEYMED BIOSCIENCES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.75 HKD | +6.04% |
|
+4.28% | -23.12% |
| Apr. 30 | Keymed Biosciences' Allergy Treatment NDA Accepted by NMPA | MT |
| Apr. 29 | Keymed Biosciences Allergy Drug Achieves Phase III Clinical Trial End Points | MT |
ETFs positioned on Keymed Biosciences Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.54% | 4 M€ | -27.92% | ||
| 0.02% | 4 M€ | -4.41% | - | |
| 0.02% | 0 M€ | +3.30% | - | |
| 0.00% | 0 M€ | +3.53% | - |
Keymed Biosciences Inc is a China-based biotechnology company. The Company focuses on the independent discovery and development of innovative biological therapies that address underserved medical needs in the autoimmune and oncology therapeutic areas. The Company has mastered in-house drug discovery and development technologies, including an innovative antibody discovery platform and a proprietary novel T cell engager (nTCE) bispecific antibody platform. The Company has also established a fully integrated platform covering the key functions of biopharmaceutical development. The Company's main products include CM310, CM326 and CMG901.
Calendar
2024-08-26
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
32.85
CNY
Average target price
53.98
CNY
Spread / Average Target
+64.34%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -23.12% | 1.26B | |
| +10.44% | 107B | |
| +0.82% | 106B | |
| +9.02% | 23.47B | |
| -13.89% | 21.9B | |
| -6.08% | 18.77B | |
| -37.26% | 17.85B | |
| -10.98% | 16.78B | |
| +8.67% | 14.41B | |
| +41.08% | 12.86B |
- Stock Market
- Equities
- 2162 Stock
- Funds and ETFs Keymed Biosciences Inc.